ABBVIE

AbbVie's stock dropped 12% after emraclidine, an investigational anti-psychotic for schizophrenia, failed Phase II trials. In contrast, Bristol Myers Squibb's KarXT, an antipsychotic acquired from Karuna Therapeutics, showed positive Phase III results, leading to a 11% stock rise for BMS.

Bristol-Myers Squibb (BMY) benefits from biopharma market growth and rival AbbVie's trial setback, with BMY stock up 10.5%. CMO Samit Hirawat's $100,000 insider purchase adds confidence. BMY leads in oncology and offers a 4.39% dividend yield. Q3 earnings beat estimates, driven by Eliquis and Opdivo, with FDA approval for Cobenfy in schizophrenia. Analysts have a 'Hold' consensus on BMY stock.

AbbVie's emraclidine fails in two Phase II schizophrenia studies, shifting focus to Parkinson's drug tavapadon from Cerevel acquisition. BMS may benefit in schizophrenia space.

AbbVie's $9 billion acquisition of Cerevel Therapeutics, centered on experimental schizophrenia drug emraclidine, failed in two clinical trials, causing a 12% drop in AbbVie's stock and a 12% rise in Bristol Myers Squibb's shares. Analysts suggest this failure may impact other companies researching muscarinic antipsychotics, with Neurocrine Biosciences and Neumora Therapeutics seeing stock fluctuations. Despite the setback, some analysts remain optimistic about the muscarinic class for schizophrenia treatment.

AbbVie disappointed with emraclidine trial results for schizophrenia, boosting Bristol Myers Squibb Co. shares.

AbbVie's emraclidine did not reduce PANSS scores in Phase II EMPOWER trial, prompting further data analysis. Despite unmet primary endpoint, a tolerable safety profile was observed. Schizophrenia affects 24 million globally, with significant under-treatment.

AbbVie's schizophrenia drug emraclidine, acquired in an $8.7 billion deal, failed two Phase 2 studies, showing numerical but not statistically significant improvements over placebo. Despite targeting muscarinic receptors to avoid D2 side effects, the drug's efficacy was lower than Bristol Myers Squibb's Cobenfy. AbbVie is analyzing data to determine next steps for emraclidine, which is also in Phase 1 testing for Alzheimer's disease psychosis.

Shares of AbbVie plummeted after its schizophrenia drug Emraclidine missed key goals in Phase 2 trials, while Bristol Myers Squibb's shares soared due to its recently approved schizophrenia treatment Cobenfy.

The article discusses the importance of enabling JavaScript for optimal app performance.

AbbVie lost $40 billion in market value after its experimental drug emraclidine failed two clinical trials for schizophrenia. Despite the setback, AbbVie remains focused on neuroscience and has a diverse portfolio of brain medicines. The failure of emraclidine removes a competitive threat for Bristol Myers' Cobenfy, an approved antipsychotic.